These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16682622)

  • 21. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
    Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
    Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
    Kancha RK; von Bubnoff N; Bartosch N; Peschel C; Engh RA; Duyster J
    PLoS One; 2011; 6(10):e26760. PubMed ID: 22046346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
    Li G; Wang X; Hibshoosh H; Jin C; Halmos B
    PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
    Ito Y; Tokudome N; Sugihara T; Takahashi S; Hatake K
    Breast Cancer; 2007; 14(2):156-62. PubMed ID: 17485900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
    Ma C; Niu X; Luo J; Shao Z; Shen K
    Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
    Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis.
    Xia W; Gooden D; Liu L; Zhao S; Soderblom EJ; Toone EJ; Beyer WF; Walder H; Spector NL
    PLoS One; 2014; 9(2):e88983. PubMed ID: 24551203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.
    Fabi A; Mottolese M; Segatto O
    J Mol Med (Berl); 2014 Jul; 92(7):681-95. PubMed ID: 24861025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
    Gayle SS; Castellino RC; Buss MC; Nahta R
    Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
    Yang ZY; Yang L; Xu CW; Wang XJ; Lei L
    Biol Open; 2020 Jan; 9(1):. PubMed ID: 31980423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
    Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
    Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
    BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
    Hong YS; Kim J; Pectasides E; Fox C; Hong SW; Ma Q; Wong GS; Peng S; Stachler MD; Thorner AR; Van Hummelen P; Bass AJ
    PLoS One; 2014; 9(10):e109440. PubMed ID: 25350844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
    Vogel C; Chan A; Gril B; Kim SB; Kurebayashi J; Liu L; Lu YS; Moon H
    Jpn J Clin Oncol; 2010 Nov; 40(11):999-1013. PubMed ID: 20542996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.